TITLE

Stock Movers

PUB. DATE
March 2013
SOURCE
BioWorld Today;3/26/2013, Vol. 24 Issue 59, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article lists stock information on several biopharmaceutical firms as of March 25, 2013 including Nasdaq Biotechnology, Array BioPharma Inc., and Cell Therapeutics Inc.
ACCESSION #
87310582

 

Related Articles

  • Stock Movers.  // BioWorld Today;7/24/2013, Vol. 24 Issue 140, p2 

    A chart is presented that lists the stock movements of biopharmaceutical firms including NASDAQ Biotechnology, Array Biopharma Inc., and Biocryst Pharmaceuticals, as of July 23, 2013.

  • Financings Roundup.  // BioWorld Today;12/7/2012, Vol. 23 Issue 237, p4 

    The article reports that 2.7 million shares of Array BioPharma Incorporated's common stock have been exercised in an overallotment option granted to underwriters via a public offering deal.

  • Financings Roundup.  // BioWorld Today;5/4/2011, Vol. 22 Issue 86, p3 

    The article reports on the plan of Boulder, Colorado-based Array BioPharma Inc. to issue 30 million U.S. dollars of its Series B Preferred Stock to those affiliated with Deerfield Partners.

  • BioWorld Stock Report For Public Biotechnology Companies.  // BioWorld Insight;2/13/2012, Vol. 20 Issue 7, p17 

    The article lists the stock report for public biotechnology companies including Acadia Pharmaceuticals Inc., AMAG Pharmaceuticals Inc., and ARRAY BioPharma Inc.

  • 08/15 (10) ARRAY BIOPHARMA INC.  // MondayMorning;8/15/2011, Vol. 19 Issue 30, p10 

    The article reports that Array Biopharma Inc. has signed a deal with Genentech Inc. to develop cancer compounds. It states that under the deal worth 685 million dollars, Genentech will have the authority over all clinical development and marketing. It mentions that the deal has led to increase...

  • Financings Roundup.  // BioWorld Today;9/21/2009, Vol. 20 Issue 181, p4 

    The article reports on an equity distribution agreement of Array Biopharma to offer and sell shares of its common stock at a price of up to 25 million U.S. dollars from time to time, with Piper Jaffray & Co. as a sales agent. The proceeds will be used by Array for interest payments under its...

  • Array's MEK Inhibitor Fails Melanoma Trial…Or Does It? Morrison, Trista // BioWorld Today;12/21/2007, Vol. 18 Issue 247, p1 

    The article reports on the failure of a Phase II trial and signal-searching studies with AZD6244 conducted by Array Biopharma Inc. as reported by its partner, AstraZeneca PLC. As a result, Array's shares declined closing down at $3.06, or 28 percent, at $7.96. The trial compared AZD6244 to...

  • Financings Roundup.  // BioWorld Today;5/7/2008, Vol. 19 Issue 89, p3 

    The article reports on the funding commitment secured by Array BioPharma Inc. in May 2008 from Deerfield Management, one of its largest shareholders. Said financing will be used to finance the company's small-molecule drug programs. Also noted is the loan structure and the common stock trading...

  • Array BioPharma Inc (Boulder CO) posted a lower-than-expected quarterly loss as operating expenses fell, sending its shares up 21% for the week.  // MondayMorning;8/20/2012, Vol. 20 Issue 33, p1 

    The article offers information on the stock market value of Boulder, Colorado-based Array BioPharma Inc. It states that the company reported a lower-than-expected quarterly loss as operating expenses fell, sending its shares up 21 percent as of August 20, 2012. It also states that the company...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics